Graft-versus-host disease (GVHD) is a common complication after a bone marrow/stem cell transplant using donor cells (allogeneic transplant). This presentation will discuss current techniques to prevent GVHD, new drugs to treat acute and chronic GVHD and clinical trials testing new GVHD therapies.

Graft versus Host Disease (GVHD) is a common complication after allogeneic stem cell transplant. Learn the difference between acute and chronic GVHD and how each develops. Both standard therapies and exciting new prevention and treatment interventions are discussed.

Several new therapies have recently been approved to prevent and treat graft-versus-host disease (GVHD) and more are being studied. The new therapies are more effective than the standard GVHD therapies and should result in a lower incidence of GVHD with fewer toxicities for patients, going forward.

Graft-versus-host-disease (GVHD) is a common challenge for patients who undergo a stem cell transplant using cells from a donor (an allogeneic transplant). It can be mild, moderate or severe. This presentation reviews the types of GVHD, the organs most often affected, common symptoms, and traditional as well as newer therapies for treating GVHD.

Graft-versus-Host-Disease (GVHD) occurs when transplanted donor cells attack the patient’s body. It can affect virtually every organ in the body and may require prolonged treatment. This presentation reviews the different types of GVHD, symptoms you should watch for and report to your doctor, and the available treatment options.

La enfermedad de injerto contra huésped (EICH) es una complicación común después de un trasplante que utiliza células de un donante (trasplante alogénico). Hay dos tipos diferentes de EICH que difieren en los órganos que afectan y en el momento en que se desarrollan normalmente. Esta presentación analiza las causas de la EICH, cómo afecta a varios órganos y las opciones de tratamiento.

Anxiety and depression are common among cancer patients and survivors. Acceptance and commitment therapy is an effective tool for these problems. This presentation discusses the mental health challenges of transplant and GVHD patients and how this therapy can help them.

Graft-versus-Host Disease (GVHD) is a common condition after a bone marrow or stem cell transplant that uses cells from a donor (an allogeneic transplant). The donor cells are called the “graft” and the patient is called the “host”. When the donor’s immune cells (the graft) are transplanted in the patient’s body (the host) they often unleash an immune system attack against the patient’s organs and tissues which can be mild, moderate or severe.

Chronic graft-versus-host disease is a common complication after a transplant using donor cells (allogeneic transplant). Early detection and treatment are critical to successful management of the disease. Side effects from drugs used to treat chronic GVHD can increase the risk of health problems later in life.

Graft-versus-Host Disease impacts a patient’s physical, emotional and spiritual quality of life. Caregivers of GVHD patients’ lives are also affected. A strong support team and setting realistic goals can improve quality of life while living with GVHD.